Effects of point mutations in the binding pocket of the mouse major urinary

protein MUP20 on ligand affinity and specificity

J. Ricatti, L. Acquasaliente, G. Ribaudo, V. De Filippis, M. Bellini, R. Esteban Llovera, S. Barollo, R. Pezzani, G. Zagotto, K. C. Persaud, C. Mucignat-Caretta

Supplementary Material S1

Structural analysis and in silico comparison of MUP20 WT and mutants

Structural comparison, including sequence alignment, structure alignment and RMSD statistics was carried out using SuperPose Version 1.0 [Rajarshi Maiti. Gary H. Van Domselaar. Haiyan Zhang. and David S. Wishart "SuperPose: a simple server for sophisticated structural superposition" Nucleic Acids Res. 2004 July 1; 32 (Web Server issue): W590W594]. The resulting 3D superimpositions between MUP20 WT and the 7 mutants are reported in the stereographic figures below, together with RMSD data.



Stereographic 3D superimposition of MUP20 WT and V59T (RMSD = 0.05).



Stereographic 3D superimposition of MUP20 WT and L88Q (RMSD = 0.04).



Stereographic 3D superimposition of MUP20 WT and Y103D (RMSD = 0.06).



Stereographic 3D superimposition of MUP20 WT and Y103R (RMSD = 0.05).



Stereographic 3D superimposition of MUP20 WT and N107L (RMSD = 0.01).



Stereographic 3D superimposition of MUP20 WT and L124V (RMSD = 0.01).



Stereographic 3D superimposition of MUP20 WT and E137K (RMSD = 0.09).

Calculated 2D interaction pattern of the ligands with MUP20 mutants



Color key of the represented interactions. Residue name and number of the interacting residues are shown in the pictures below, together with the distance between the ligand and the residue (expressed in Å). Pictures were obtained using Discovery Studio (Dassault Systèmes BIOVIA. San Diego).



MUP20 WT



MUP20 WT



2D interaction pattern of PYR.



MUP20 WT



2D interaction pattern of L-ADR.





2D interaction pattern of OCT.











2D interaction pattern of L-ADR.





L88Q

2D interaction pattern of PYR.



2D interaction pattern of OCT.













2D interaction pattern of L-ADR.



2D interaction pattern of 2,4-DMP.



Y103D





2D interaction pattern of OCT.





2D interaction pattern of MEN.



Y103D



2D interaction pattern of L-ADR.









2D interaction pattern of OCT.



Y103R



2D interaction pattern of MEN.











N107L







2D interaction pattern of OCT.









2D interaction pattern of LIN.

N107L



2D interaction pattern of L-ADR.



L124V







2D interaction pattern of OCT.



















2D interaction pattern of 2,4-DMP.









2D interaction pattern of OCT.













2D interaction pattern of L-ADR.



Analysis of interacting residues

Protein	Ligand	Energy (-kcal/mol)	Interacting residues	Distance (Å)	Ligand-residue interaction
	ОСТ	4.7	lle168	4.20	hydrophobic
			Met57	5.48	hydrophobic
			Val59	4.79	hydrophobic
	MEN	7.5	Leu124	3.37	π-σ
			Leu135	3.74	hydrophobic
			Phe75	5.04	π-π
			Asn107	3.37	van der Waals
			Val59	4.90	π-alkyl
			Leu124	3.82	π-σ
			Met57	5.20	π-sulfur
	PYR	5.9	Leu135	4.52	hydrophobic
			Tyr103	4.61	hydrophobic
			Val101	4.87	hydrophobic
			Leu88	4.66	hydrophobic
			Phe75	3.90	π-alkyl
MUP20					
		6.0	Val101	4.95	hydrophobic
			Leu124	4.65	hydrophobic
	LIN		Tyr103	4.52	hydrophobic
			Phe75	4.10	π-alkyl
			Leu88	4.07	hydrophobic
			Arg58	2.54	van der Waals
			Asn174	2.08	Hydrogen bond
	L-ADR	5.7	Leu43	2.56	Hydrogen bond
			lle51	5.45	hydrophobic
			Ala173	4.79	hydrophobic
			Met57	4.78	hydrophobic
			Leu124	3.77	π-alkyl
		6.4	Val59	4.96	hydrophobic
	2,4-DIVIP	0.4	Tyr103	4.98	π-π
			Leu88	4.46	hydrophobic
			Phe75	4.23	π-π
			lle168	3.84	Hydrogen bond
VEOT	ОСТ	5.2	Leu43	4.13	Hydrogen bond
V291			lle51	4.76	hydrophobic

			Met57	4.65	hydrophobic	
	MEN	7.7	Leu124	5.19	π-σ	
			Leu135	4.75	hydrophobic	
			Leu43	4.42	hydrophobic	
			Glu52	Hydrogen bond		
	PYR	5.1	lle51	5.29	π-alkyl	
			Ala173	4.84	hydrophobic	
			Leu170	4.46	hydrophobic	
			Arg58	5.15	Hydrogen bond	
		5.0	lle51	4.75	hydrophobic	
	LIN	5.0	lle168	4.34	hydrophobic	
			Arg48	4.77	hydrophobic	
			Arg58	3.83	Hydrogen bond	
	L-ADR	5.4	lle51	3.37	Hydrogen bond	
			Leu43	5.14	π-alkyl	
			Thr59	3.65	Hydrogen bond	
			Leu124	5.87	π-alkyl	
			Val101	4.93	hydrophobic	
	2,4-DMP	6.4	Tyr103	5.72	π-π	
			Leu88	5.29	hydrophobic	
			Phe75	4.51	π-alkyl	
			lle168	2.94	Hydrogen bond	
	ОСТ	5.0	Leu43	4.21	Hydrogen bond	
			lle51	4.46	hydrophobic	
			Leu43	4.46	hydrophobic	
	MEN	6.4	Arg58	5.20	Hydrogen bond	
			Leu170	4.34	hydrophobic	
			Leu43	4.31	hydrophobic	
1000	DVD	F 4	lle51	5.29	π-alkyl	
188Q	PYR	5.1	Ala173	4.90	hydrophobic	
			Leu170	4.72	hydrophobic	
			Leu73	4.31	hydrophobic	
	LIN	5.8	Val101	Val101 4.78 hydro		
			Tyr103	4.22	π-alkyl	
		F 0	Tyr103	3.54	π-π	
	L-AUK	5.9	Phe75	5.26	π-π	

			Leu135	4.86	hydrophobic
		6.2	Leu124	4.71	π-alkyl
	2,4-DIVIP	0.3	Val59	4.68	hydrophobic
			Phe75	4.17	π-alkyl
	тоо	4 7	lle168	3.68	Hydrogen bond
	001	4.7	Asn166	5.41	Hydrogen bond
			Ala173	5.50	π-alkyl
	NAENI	6.4	Arg58	5.21	Hydrogen bond
	IVILIN	0.4	Leu170	4.33	hydrophobic
			Leu43	4.42	hydrophobic
			leu124	4.52	π-alkyl
			Leu135	5.25	hydrophobic
	PYR	5.2	Leu88	4.88	hydrophobic
			Phe75	3.91	π-alkyl
			Val59	4.30	van der Waals
Y103D					
			Leu73	3.09	Hydrogen bond
	LIN	4.7	lle168	4.78	Hydrogen bond
			Ala173	4.88	hydrophobic
		5.2	Leu43	3.93	Hydrogen bond
	L-ADR		lle168	3.79	Hydrogen bond
			Glu52	5.21	Hydrogen bond
			lle51	5.25	Hydrogen bond
			Asn107	4.24	Hydrogen bond
	2 4-DMP	5.6	Leu124	5.14	π-alkyl
	2,4-01011	5.0	Val59	4.82	hydrophobic
			Phe75	5.15	hydrophobic
	ОСТ	18	Arg103	3.19	Hydrogen bond
	001	4.0	Phe109	4.80	hydrophobic
	MEN	61	Leu71	5.06	π-alkyl
		0.1	lle111	5.10	hydrophobic
Y03R			lle111	4.93	π-alkyl
	DVR	45	lle34	5.25	hydrophobic
		ч.5	lle64	5.11	hydrophobic
			Leu71	4.40	hydrophobic
	LIN	4 8	lle111	4.28	hydrophobic
	LIIN	4.0	lle34	5.30	hydrophobic

	L-ADR	4.5	lle111	5.26	Hphp
			lle111	4.33	hydrophobic
			lle122	4.37	hydrophobic
		4.0	lle120	5.28	hydrophobic
	2,4-DIVIP	4.9	lle64	5.03	hydrophobic
			Leu71	4.08	hydrophobic
			Leu43	4.89	hydrophobic
			lle168	3.99	Hydrogen bond
	ОСТ	F 1	Leu43	4.13	Hydrogen bond
	UCI	5.1	Arg58	3.93	hydrophobic
			Phe60	4.73	hydrophobic
			Arg58	5.20	Hydrogen bond
	MEN	6.4	Leu170	4.34	hydrophobicb
			Leu43	4.45	hydrophobic
			Glu52	4.22	Hydrogen bond
	PYR	5.1	lle51	5.28	hydrophobic
			Ala173	4.85	hydrophobic
			Leu43	4.36	hydrophobic
			Leu170	4.70	hydrophobic
N107L			Tyr103	4.62	π-alkyl
			Leu88	5.37	hydrophobic
			Phe109	4.70	hydrophobic
	LIN	5.8	Val101	4.50	hydrophobic
			Leu73	4.94	hydrophobic
			Phe75	3.94	π-alkyl
			Tyr103	5.40	π-π
	L-ADR	5.3	Val59	5.40	π-alkyl
			Leu124	5.49	π-alkyl
			Leu135	4.83	hydrophobic
			Leu124	4.70	π-alkyl
	2,4-DMP	6.5	Tyr103	4.67	π-alkyl
			Phe75	5.23	π-π
			Val59	5.06	hydrophobic
	ОСТ	6.3	Val101	5.08	hydrophobic
142414					
LIZ4V		7 5	Val101	4.85	hydrophobic
	IVIEN	7.5	Val124	4.86	hydrophobic

			Tyr103	4.86	hydrophobic
			Val124	5.14	π-alkyl
			Phe75	Phe75 4.21	
	PYR	6.0	Val101	5.03	hydrophobic
			Tyr103 4.30		hydrophobic
			Val59	4.94	π-alkyl
			Arg58	4.38	Hydrogen bond
	LIN	5.2	lle168	4.35	hydrophobic
			lle51	4.32	hydrophobic
			Tyr103	3.55	Hydrogen bond
	L-ADR	6.1	Asn107	4.74	Hydrogen bond
			Val124	5.21	π-alkyl
			Val59	4.73	hydrophobic
		6.1	Tyr103	4.57	π-π
	2,4-DIVIP	0.1	Phe75	4.95	π-π
			Val101	4.97	hydrophobic
	OCT	5.3	Phe60	4.58	hydrophobic
				4.00	
	MEN	7.4	Leu124	4.99	π-аку
			Leu135	4.50	nydrophobic
			IVIELS7	4.57	ηγατορησοις
		5.8	Leu124	5.40	π-alkvl
	PYR		Val59	5.10	hvdrophobic
			Tvr103	4.30	hydrophobic
			Val101	5.17	hydrophobic
			Phe75	5.04	π-alkyl
			lle51	3.71	Hydrogen bond
E137K		F 0	Arg58	Arg58 4.49 Hy	
	LIN	5.0	Arg48	4.56	hydrophobic
			lle168	4.54	hydrophobic
			lle168	3.96	Hydrogen bond
	I-ADR	52	Leu43	3.95	Hydrogen bond
	L / IBN	5.2	Arg58	4.76	Hydrogen bond
			Leu170	5.43	hydrophobic
			Leu135	4.88	hydrophobic
	2,4-DMP	6.2	Leu124	4.68	π-alkyl
			Tyr103	5.25	π-alkyl
			Phe75	4.15	π-alkyl

Supplementary Material S2

S2a. List of selected aminoacids for mutation and mutation scheme

V59, L88, Y103, N107, L124, E137.

Mutation and alignment Scheme

7 mutated proteins: MUP20V59T, MUP20L88Q, MUP20Y103D, MUP20Y103R, MUP20N107L, MUP20L124V, MUP20E137K.

CLUSTAL format	alignment by MAFFT (v7	.243)
MUP20wt	MHHHHHHMKLLVLLLCL	GLTLVCVHAEEASSMERNFNVEKINGEWYTIMLATDKRE
MUP20V59T	MMGSSHHHHHHIE	GREEASSMERNFNVEKINGEWYTIMLATDKRE
MUP20L124V	MMGSSHHHHHHIE	GREEASSMERNFNVEKINGEWYTIMLATDKRE
MUP20E137K	MMGSSHHHHHHIE	GREEASSMERNFNVEKINGEWYTIMLATDKRE
MUP20L88Q	MMGSSHHHHHHIE	GREEASSMERNFNVEKINGEWYTIMLATDKRE
MUP20N107L	MMGSSHHHHHHIE	GREEASSMERNFNVEKINGEWYTIMLATDKRE
MUP20Y103R	MMGSSHHHHHHIE	GREEASSMERNFNVEKINGEWYTIMLATDKRE
MUP20Y103D	MMGSSHHHHHHIE	GREEASSMERNFNVEKINGEWYTIMLATDKRE
	* *****::	*****
MUP20wt	KIEEHGSMRVFVEYIHVLENS	LALKFHIIINEECSEIFLVADKTEKAGEYSVTYDGSNTF
MUP20V59T	KIEEHGSMRTFVEYIHVLENS	LALKFHIIINEECSEIFLVADKTEKAGEYSVTYDGSNTF
MUP20L124V	KIEEHGSMRVFVEYIHVLENS	LALKFHIIINEECSEIFLVADKTEKAGEYSVTYDGSNTF
MUP20E137K	KIEEHGSMRVFVEYIHVLENS	LALKFHIIINEECSEIFLVADKTEKAGEYSVTYDGSNTF
MUP20L88Q	KIEEHGSMRVFVEYIHVLENS	LALKFHIIINEECSEIFQVADKTEKAGEYSVTYDGSNTF
MUP20N107L	KIEEHGSMRVFVEYIHVLENS	LALKFHIIINEECSEIFLVADKTEKAGEYSVTYDGSNTF
MUP20Y103R	KIEEHGSMRVFVEYIHVLENS	LALKFHIIINEECSEIFLVADKTEKAGEYSVTRDGSNTF
MUP20Y103D	KIEEHGSMRVFVEYIHVLENS	LALKFHIIINEECSEIFLVADKTEKAGEYSVTDDGSNTF
	******** • **********	****************
MUP20wt	TILKTDYDNYIMIHLINKKDG	ETFQLMELYGREPDLSSDIKEKFAQLSEEHGIVRENIID
MUP20V59T	TILKTDYDNYIMIHLINKKDG	ETFQLMELYGREPDLSSDIKEKFAQLSEEHGIVRENIID
MUP20L124V	TILKTDYDNYIMIHVINKKDG	ETFQLMELYGREPDLSSDIKEKFAQLSEEHGIVRENIID
MUP20E137K	TILKTDYDNYIMIHLINKKDG	ETFQLMKLYGREPDLSSDIKEKFAQLSEEHGIVRENIID
MUP20L88Q	TILKTDYDNYIMIHLINKKDG	ETFQLMELYGREPDLSSDIKEKFAQLSEEHGIVRENIID
MUP20N107L	TILKTDYDLYIMIHLINKKDG	ETFQLMELYGREPDLSSDIKEKFAQLSEEHGIVRENIID
MUP20Y103R	TILKTDYDNYIMIHLINKKDG	ETFQLMELYGREPDLSSDIKEKFAQLSEEHGIVRENIID
MUP20Y103D	TILKTDYDNYIMIHLINKKDG	ETFQLMELYGREPDLSSDIKEKFAQLSEEHGIVRENIID
	****** **********	*****
MUP20wt	LTNANRCLEARE	
MUP20V59T	LTNANRCLEARE	
MUP20L124V	LTNANRCLEARE	
MUP20E137K	LTNANRCLEARE	
MUP20L88Q	LTNANRCLEARE	
MUP20N107L	LTNANRCLEARE	
MUP20Y103R	LTNANRCLEARE	
MUP20Y103D	LTNANRCLEARE	
	* * * * * * * * * * *	

Figure S2a Clustal alignment of amino acid sequences

S2b. Expression Procedure

For the heterologous expression 100µl of DE3 BL21 *E. coli* cells strains were used, after the preparation of competent bacteria, followed by a heat shock transformation with 10µl of ligation product containing the plasmid including the ampicillin resistance gene. Transformants carrying the plasmid for wild-type or mutant MUP20 were plated in LB-agar 100µg/ml ampicillin Petri dishes and incubated overnight at 37°C. In order to proceed with the small scale expression of the recombinant proteins, a set of single antibiotic resistant colony was selected to inoculate 5 ml of ampicillin-LB media and incubated with shaking 250 rpm at 37°C. The turbid liquid cultures (positives) were selected for the bacterial growing step.

From each liquid culture 750 µl were mixed with 75 ml of ampicillin-LB media, shaken at 300 rpm at 37°C until the OD600 reached 0.4-0.6. Subsequently, for transcription of the gene of interest, the protein expression was induced by isopropyl-b-D-thiogalactoside (0.4mM, BioChemica, EuroClone, Milan, Italy) and shaken at 350 rpm at 37°C for 3 hours. The liquid culture was centrifuged at 5000 rpm for 10', and pellets were collected and sampled to confirm the presence of the protein via SDS-page.

Figure S1b shows an example of MUP expression, SDS-PAGE (15% acrylamide) analysis of recombinant MUP under reducing conditions. Lane 1 depicts MUP20 L88Q before induction and lane 2 after induction. Lane 3 shows MUP20 L124V before induction and lane 4 after induction. On the right, molecular weight markers are shown. The original gel is shown in Figure S1c.



Figure S2b SDS-PAGE of recombinant MUPs



Figure S2c. Unmodified scanning of the gel showed in Fig. S1b.

Supplementary Material S 3

MUP MW (experimental) – a.m.u MW (theoretical) – a.m.u. WT 20625.2 21883.97 L88Q 20621.4 20682.16 L124V 20653.5 20653.16 Y103R 20628.3 20660.20

Measured molecular weights from Mass Spectrometry and theoretical values

Supplementary Material S4. Measured Kd (μ M)

	WT		V59T		L88Q		Y103D)	Y103R		N107I	-	L124V		E137K	[
Ligand	Kd	SD	Kd	SD	Kd	SD	Kd	SD	Kd	SD	Kd	SD	Kd	SD	Kd	SD
PYR	1.29	0.0	1.9	0.00	1.39	0.01	0.84	0.04	0.74	0.00	1.40	0.01	0.07	0.01	1.52	0.02
		1	3													
LIN	2.82	0.0	1.6	0.00	2.21	0.01	2.17	0.06	5.93	0.11	1.37	0.02	0.29	0.01	1.85	0.05
		4	0													
2,4-DMP	4.24	0.0	1.4	0.02	5.08	0.29	4.68	0.09	11.92	0.09	1.99	0.03	1.30	0.06	4.05	0.04
		7	4													
ОСТ	0.78	0.0	1.5	0.02	1.45	0.03	0.92	0.01	1.88	0.01	2.67	0.08	0.36	0.00	3.20	0.01
		0	4													
MEN	0.61	0.0	1.8	0.06	1.31*	0.06	0.82*	0.10	1.33*	0.06	1.23	0.05	0.07*	0.01	2.14	0.29
	*	4	5													
L-ADR	5.31	0.0	0.8	0.01	11.24	0.58	3.34	0.25	7.06	0.23	0.90	0.03	1.33	0.06	4.07	0.45
		6	7													

*data from Scorsone et al., IEEE Sensors Journal 2016, 16, 6543, Tab. 1.

Supplementary Material S5. Binding data

1.00 uM 1.60 uM	MUP20x6HisWT Ligand 2-isobutyl-3-methoxypyrazine Linalool 2-4-dimethylphenol 2-butyl-1-octanol MEN L-ADR	first se Kd Kd 2.85 4.20 0.78 0.64 5.36	cond 1.28 2.80 4.29 0.78 0.59 5.27	mean Kd SD 1.29 0.01 2.82 0.04 4.24 0.07 0.78 0.00 0.61 0.04 5.31 0.06	Ligand 2-isobutyl-3-methoxypyrazine Linalool 2.4-dimethylphenol 2-butyl-1-octanol MEN L-ADR	first second Ka - 1 Ka - 2 0.77 0.78 0.35 0.36 0.24 0.23 1.28 1.28 1.56 1.71 0.19 0.19	Ka mean Ka SD 0.78 0.01 0.35 0.01 0.24 0.00 1.28 0.00 1.63 0.10 0.19 0.00	=(IC-50/(1+1-NPNfree/1-NPNkd) Kd 1-NPN 0.65 1+1-NPNfree/Kd 2.43
1.00 uM 1.60 uM	MUP20x6HisV59T Ligand 2-isobutyl-3-methoxypyrazine Linalool 2-4-dimethylphenol 2-butyl-1-octanol Menadione L-Adrenaline	Kd Kd 1.93 1.60 1.42 1.55 1.89 0.86	Kd 1.94 1.60 1.45 1.52 1.80 0.88	mean Kd SD 1.93 0.00 1.60 0.00 1.44 0.02 1.54 0.02 1.85 0.06 0.87 0.01	Ligand 2-isobutyl-3-methoxypyrazine Linalool 2.4-dimethylphenol 2-butyl-1-octanol Menadione L-Adrenaline	Ka - 1 Ka - 2 0.52 0.52 0.63 0.62 0.70 0.69 0.64 0.66 0.53 0.55 1.16 1.14	Ka mean Ka SD 0.52 0.00 0.62 0.00 0.70 0.01 0.65 0.01 0.54 0.02 1.15 0.02	=(IC-50/(1+1-NPN/ree/1-NPNkd) Kd 1-NPN 0.46 1+1-NPN/ree/Kd 3.09
1.00 uM 1.60 uM	MUP20x6HisL88Q Ligand 2-isobutyl-3-methoxypyrazine Linalool 2-4-dimethylphenol 2-butyl-1-octanol Menadione L-Adrenaline	Kd Kd 1.39 2.21 5.28 1.48 1.27 11.65	Kd 1.40 2.20 4.88 1.43 1.36 10.83	mean Kd SD 1.39 0.01 2.21 0.01 5.08 0.29 1.45 0.03 1.31 0.06 11.24 0.58	Ligand 2-isobutyl-3-methoxypyrazine Linalool 2.4-dimethylphenol 2-butyl-1-octanol Menadione L-Adrenaline	Ka - 1 Ka - 2 0.72 0.71 0.45 0.45 0.19 0.21 0.68 0.70 0.79 0.74 0.09 0.09	Ka mean Ka SD 0.72 0.00 0.45 0.00 0.20 0.01 0.69 0.02 0.76 0.04 0.09 0.00	=(IC-50/(1+1-NPNlfree/1-NPNkd) Kd 1-NPN 2.07 1+1-NPNfree/Kd 1.46
1.00 uM 1.60 uM	MUP20x6HisY103D Ligand 2-isobutyl-3-methoxypyrazine Linalool 2.4-dimethylphenol 2.4-dimethylphenol 2-butyl-1-octanol Menadione L-Adrenaline	Kd Kd 0.87 2.21 4.61 0.91 0.75 3.17	Kd 0.82 2.13 4.74 0.92 0.89 3.52	mean Kd SD 0.84 0.04 2.17 0.06 4.68 0.09 0.92 0.01 0.82 0.10 3.34 0.25	Ligand 2-isobutyl-3-methoxypyrazine Linalool 2.4-dimethylphenol 2-butyl-1-octanol Menadione L-Adrenaline	Ka - 1 Ka - 2 1.15 1.22 0.45 0.47 0.22 0.21 1.09 1.08 1.32 1.12 0.32 0.28	Ka mean Ka SD 1.18 0.05 0.46 0.01 0.21 0.00 1.09 0.01 1.22 0.15 0.30 0.02	=(IC-50/(1+1-NPNfree/1-NPNkd) Kd 1-NPN 1.57 1+1-NPNfree/Kd 1.55
1.00 uM 1.60 uM	MUP20x6HisY103R Ligand 2-isobutyl-3-methoxypyrazine Linalool 2.4-dimethylphenol 2-butyl-1-octanol Menadione L-Adrenaline	Kd Kd 0.74 5.86 11.86 1.88 1.37 7.22	Kd 0.74 6.01 11.98 1.88 1.29 6.90	mean Kd SD 0.74 0.00 5.93 0.11 11.92 0.09 1.88 0.01 1.33 0.06 7.06 0.23	Ligand 2-isobutyl-3-methoxypyrazine Linalool 2.4-dimethylphenol 2-butyl-1-octanol Menadione L-Adrenaline	Ka - 1 Ka - 2 1.36 1.36 0.17 0.17 0.08 0.08 0.53 0.53 0.73 0.77 0.14 0.14	Ka mean Ka SD 1.36 0.00 0.17 0.00 0.08 0.00 0.53 0.00 0.75 0.03 0.14 0.00	=(IC-50/(1+1-NPNfree/1-NPNkd) Kd 1-NPN 4.39 1+1-NPNfree/Kd 1.21
1,00 uM 1,60 uM	MUP20x6HisN107L Ligand 2-isobutyl-3-methoxypyrazine Linalool 2.4-dimethylphenol 2-butyl-1-octanol Menadione L-Adrenaline	Kd Kd 1.40 1.39 1.97 2.73 1.19 0.92	Kd 1.39 1.36 2.01 2.62 1.27 0.88	mean Kd SD 1.40 0.01 1.39 0.02 1.99 0.03 2.67 0.08 1.23 0.05 0.90 0.03	Ligand 2-isobutyl-3-methoxypyrazine Linalool 2.4-dimethylphenol 2-butyl-1-octanol Menadione L-Adrenaline	Ka - 1 Ka - 2 0.71 0.72 0.51 0.50 0.51 0.50 0.37 0.38 0.84 0.79 1.09 1.14	Ka mean Ka SD 0.72 0.00 0.73 0.01 0.50 0.01 0.81 0.03 1.11 0.03	=(IC-50/(1+1-NPNfree/1-NPNkd) Kd 1-NPN 0.85 1+1-NPNfree/Kd 2.05
1.00 uM 1.60 uM	MUP20x6HisL124V Ligand 2-isobutyl-3-methoxypyrazine Linalool 2.4-dimethylphenol 2-butyl-1-octanol Menadione L-Adrenaline	Kd Kd 0.06 0.30 1.34 0.36 0.06 1.29	Kd 0.07 0.29 1.26 0.36 0.07 1.37	mean Kd SD 0.07 0.01 0.29 0.01 1.30 0.06 0.36 0.00 0.07 0.01 1.33 0.06	Ligand 2-isobutyl-3-methoxypyrazine Linalool 2.4-dimethylphenol 2-butyl-1-octanol Menadione L-Adrenaline	Ka - 1 Ka - 2 17.00 13.42 3.34 3.46 0.74 0.79 2.79 2.76 17.49 13.34 0.78 0.73	Ka mean Ka SD 15.21 2.53 3.40 0.09 0.77 0.03 2.78 0.02 15.42 2.93 0.75 0.03	=(IC-50/(1+1-NPNfree/1-NPNkd) Kd 1-NPN 0.22 1+1-NPNfree/Kd 5.03
1.00 uM 1.60 uM	MUP20x6HisE137K Ligand 2-isobutyl-3-methoxypyrazine Linalool 2.4-dimethylphenol 2-butyl-1-octanol Menadione L-Adrenaline	Kd Kd 1.51 1.82 4.02 3.19 1.93 3.75	Kd 1.54 4.07 3.20 2.34 4.39	mean Kd SD 1.52 0.02 1.85 0.05 4.05 0.04 3.20 0.01 2.14 0.29 4.07 0.45	Ligand 2-isobutyl-3-methoxypyrazine Linalool 2.4-dimethylphenol 2-butyl-1-octanol Menadione L-Adrenaline	Ka - 1 Ka - 2 0.66 0.65 0.55 0.53 0.25 0.25 0.31 0.31 0.52 0.43 0.27 0.23	Ka mean Ka SD 0.66 0.01 0.54 0.01 0.25 0.00 0.31 0.00 0.47 0.06 0.25 0.03	=(IC-50/(1+1-NPNfree/1-NPNkd) Kd 1-NPN 1.36 1+1-NPNfree/Kd 1.65